Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Yu Ri Kim, Jin Seok Kim, Soo Jeong Kim, Hyun Ae Jung, Seok Jin Kim, Won Seog Kim, Hye Won Lee, Hyeon Seok Eom, Seong Hyun Jeong, Joon Seong Park, June Won Cheong, Yoo Hong Min

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

Original languageEnglish
Article number34
JournalJournal of Hematology and Oncology
Volume4
DOIs
Publication statusPublished - 2011 Aug 17

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Kim, Y. R., Kim, J. S., Kim, S. J., Jung, H. A., Kim, S. J., Kim, W. S., Lee, H. W., Eom, H. S., Jeong, S. H., Park, J. S., Cheong, J. W., & Min, Y. H. (2011). Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. Journal of Hematology and Oncology, 4, [34]. https://doi.org/10.1186/1756-8722-4-34